

1 **Mitochondrial-Derived Compartments Facilitate Cellular Adaptation to Amino**
2 **Acid Stress**

3

4 **Max-Hinderk Schuler^{1#}, Alyssa M. English^{1#}, Tianyao Xiao¹, Thane J. Campbell¹,**
5 **Janet M. Shaw¹, and Adam L. Hughes^{1,2,*}**

6

7 ¹Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT,
8 84112, USA

9

10 ²Lead Contact

11

12 #These authors contributed equally to this work

13 *Correspondence: hughes@biochem.utah.edu

14

15

16

17

18

19

20

21

22

23

24

25 **PAPER SUMMARY**

26 Amino acids are essential building blocks of life. However, increasing evidence
27 suggests that elevated amino acids cause cellular toxicity associated with numerous
28 metabolic disorders. How cells cope with elevated amino acids remains poorly
29 understood. Here, we show that a previously identified cellular structure, the
30 mitochondrial-derived compartment (MDC), functions to protect cells from amino acid
31 stress. In response to amino acid elevation, MDCs are generated from mitochondria,
32 where they selectively sequester and deplete SLC25A nutrient carriers and their
33 associated import receptor Tom70 from the organelle. Generation of MDCs promotes
34 amino acid catabolism, and their formation occurs simultaneously with transporter
35 removal at the plasma membrane via the multi-vesicular body (MVB) pathway.
36 Combined loss of vacuolar amino acid storage, MVBs and MDCs renders cells sensitive
37 to high amino acid stress. Thus, we propose that MDCs operate as part of a
38 coordinated cell network that facilitates amino acid homeostasis through post-
39 translational nutrient transporter remodeling.

40

41

42

43

44

45

46

47

48 **STAR METHODS**

49
50 **Resource Availability**

51 Lead Contact

52 Further information and requests for resources and reagents should be directed to and
53 will be fulfilled by the Lead Contact, Adam Hughes (hughes@biochem.utah.edu). All
54 unique/stable reagents generated in this study are available from the Lead Contact
55 without restrictions.

56
57 Materials Availability

58 All unique/stable reagents generated in this study are available from the Lead Contact
59 without restrictions.

60
61 Data and Code Availability

- 62
- 63 • Metabolomics data have been deposited at and are publicly available as of the
64 date of the publication. Accession numbers are listed in the Key Resources
65 Table. All other data reported in this paper will be shared by the lead contact
66 upon request.
 - 67 • This paper does not report original code.
 - 68 • Any additional information required to reanalyze the data reported in this paper is
69 available from the lead contact upon request.

70 **Experimental Model and Subject Details**

71 Yeast Strains

72 All yeast strains are derivatives of *Saccharomyces cerevisiae* S288c (BY)
73 (Brachmann et al., 1998). Strains expressing fluorescently tagged *TOM70*, *TIM50*,
74 *TOM20*, *ILV2*, *TCD2*, *BAP2*, *OAC1*, *ODC1*, *MTM1*, *YMC2* and/or AID*-6xFLAG/6xFLAG
75 tagged *VMA2* from their native loci were created by one step PCR-mediated carboxy-
76 terminal endogenous epitope tagging using standard techniques and oligo pairs listed in
77 Table S2. Plasmid templates for fluorescent epitope tagging were from the pKT series
78 of vectors (Sheff and Thorn, 2004). Plasmids used for AID*-6xFLAG/6xFLAG tagging
79 and integration of GPD-OsTir1 into the *LEU2* locus are described below. Correct
80 integrations were confirmed by a combination of colony PCR across the chromosomal
81 insertion site and correctly localized expression of the fluorophore by microscopy.
82 Deletion strains for *TOM70*, *TOM71*, *TOM20*, *GEM1*, *PEP4*, *ILV2*, *BAT1* and/or *BAT2*,
83 *VPS27* and/or *DID4* were generated by one step PCR-mediated gene replacement with
84 the indicated selection cassette using standard techniques and oligo pairs listed in
85 Table S2. Plasmid templates for gene replacement were from the pRS series of vectors
86 (Sikorski and Hieter, 1989). Correct insertion of the selection cassette into the target
87 gene was confirmed by colony PCR across the chromosomal insertion site. Yeast
88 strains constitutively expressing *TOM70*, *TOM20*, *TIM50* or the indicated mitochondrial
89 carrier protein from the GPD promoter were generated by integration of the expression
90 cassette into yeast chromosome I (199456-199457). Plasmids for integration of the
91 GPD-driven expression cassette are described below. Correct insertion of the
92 expression cassette into chromosome I was confirmed by colony PCR across the
93 chromosomal insertion site.

94 *Wild-type* yeast strain AHY4706, which was rendered prototrophic with pHLUM
95 (see below) to prevent complications caused by amino acid auxotrophies in the BY
96 strain background, was used to quantify amino acid dependencies of MDC formation
97 and for analysis of whole cell metabolite levels. *Wild-type* yeast strains AHY5082,
98 AHY7053, AHY7620, AHY8529, AHY8531, AHY6257, AHY10448, AHY10466,
99 AHY10468 and AHY10470 were used for super resolution and/or time-lapse imaging.
100 AHY1447 and AHY10546 were used for indirect immuno fluorescence analysis. *Wild-*
101 *type* and *gem1* Δ yeast strains AHY4706, AHY4057, AHY6259, AHY7802, AHY10448,
102 AHY10554, AHY10466, AHY10552, AHY10468, AHY10548, AHY10470, AHY10550,
103 AHY7808, AHY7816, AHY7804 and AHY7806 were used for quantification of MDC-
104 dependent removal of proteins from mitochondria and protein enrichment in the MDC.
105 Metabolite analysis was performed in AHY4706, AHY9666, BY4741, AHY4230,
106 AHY9873 and AHY10141. Growth assays were performed with BY4741, AHY4230,
107 AHY9873, AHY10141, AHY9913 and AHY10145. A complete list of all strains used in
108 this manuscript can be found in the Key Resources Table.

109

110 Yeast Cell Culture and Media

111 Yeast cells were grown exponentially for 15 hours at 30 °C to a maximum density
112 of 6×10^6 cells/mL before the start of all experiments described in the paper, including
113 MDC and spot assays. This period of overnight log-phase growth was carried out to
114 ensure vacuolar and mitochondrial uniformity across the cell population and is essential
115 for consistent MDC activation. Cells were cultured as indicated in media containing high
116 amino acids (1 % yeast extract, 2 % peptone, 0.005 % adenine, 2 % glucose) or low

117 amino acids (0.67 % yeast nitrogen base without amino acids, 2 % glucose,
118 supplemented nutrients 0.074 g/L each adenine, alanine, arginine, asparagine, aspartic
119 acid, cysteine, glutamic acid, glutamine, glycine, histidine, myo-inositol, isoleucine,
120 lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, uracil,
121 valine, 0.369 g/L leucine, 0.007 g/L para-aminobenzoic acid). For growth in medium
122 lacking all amino acids (0.67 % yeast nitrogen base without amino acids, 2 % glucose),
123 cells were cultured in low amino acid medium and then shifted to medium containing no
124 amino acids at time of drug treatment. Where casamino acids were added to low or no
125 amino acid media, casamino acids were added at time of drug treatment to a final
126 concentration of 2 %. For single amino acid re-addition experiments, individual amino
127 acids were added to medium containing low amino acids at the time of drug treatment.
128 All amino acids were added to a final concentration of 20 mg/mL, except indicated
129 otherwise, with the exception of cysteine and tyrosine, which were added at final
130 concentrations of 5 mg/mL and 1 mg/mL respectively, due to toxicity and/or solubility
131 issues. Leucine and methionine catabolites were added at a final concentration of
132 10 mM at the time of drug treatment. Drugs were added to cultures at final
133 concentrations of concanamycin A (500 nM), cycloheximide (10 µg/mL), rapamycin
134 (250 nM), torin1 (5 µM), antimycin A (40 µM), FCCP (10 µM), oligomycin (10 µM), H₂O₂
135 (10 µM), CoCl₂ (1 mM), tunicamycin (5 µg/ml) and BPS (250 µM). Iron was added to
136 cultures as (NH₄)₂Fe(SO₄)₂(H₂O)₆ at a final concentration of 2 mM.

137

138 **Method Details**

139

140 Extraction of Whole Cell Metabolites from Yeast

141 For analysis of whole cell metabolite levels in high amino acid media, cells were
142 grown exponentially in high amino acid media for 15 hours to a maximum density of
143 6×10^6 cells/mL, resuspended in fresh media to a maximum density of 1.85×10^7
144 cells/mL, and treated for three hours with the indicated drugs. 5×10^7 total yeast cells
145 were harvested by centrifugation for two minutes at $5000 \times g$, washed once with ice cold
146 water, and cell pellets were shock frozen in liquid nitrogen. Glucose tracing experiments
147 were performed as described above, but cells were resuspended in high amino acid
148 media containing 2 % $^{13}C_6$ -Glucose (Cambridge Isotope Laboratories). For analysis of
149 whole cell metabolite levels in low amino acid media supplemented with leucine, cells
150 were grown exponentially in low amino acid media for 15 hours to a maximum density of
151 6×10^6 cells/mL, resuspended in low amino acid media supplemented with 10 mg/ml
152 leucine to a maximum density of 1.85×10^7 cells/mL and treated for three hours with
153 ConcA. 5×10^7 total yeast cells were harvested by fast quenching into four volumes of
154 100 % methanol at $-40 \text{ }^\circ\text{C}$ (final 80 % methanol), pelleted by centrifugation for two
155 minutes at $5000 \times g$ in a pre-cooled rotor at $-20 \text{ }^\circ\text{C}$, washed once with $-40 \text{ }^\circ\text{C}$ cold 80 %
156 methanol, and cell pellets were shock frozen in liquid nitrogen.

157 Whole cell metabolites were extracted from yeast cell pellets as previously
158 described with slight modifications (Canelas et al., 2009). Briefly, 0.4 μg of the internal
159 standard succinic- d_4 acid (Sigma Aldrich 10907HD) was added to each sample.
160 Subsequently, 5 mL of boiling 75% EtOH were added to each cell pellet, followed by
161 vortex mixing and incubation at $90 \text{ }^\circ\text{C}$ for five minutes. Cell debris were removed by
162 centrifugation for three minutes at $7000 \times g$ and supernatants were transferred to new

163 tubes and dried *en vacuo*. Pooled quality control samples were made by removing a
164 fraction of collected supernatant from each sample and process blanks were made
165 using only extraction solvent and no cell culture pellet.

166

167 GC-MS Analysis

168 GC-MS analysis was performed with an Agilent 5977B GC-MS MSD-HES or an Agilent
169 7200 GC-QToF-MS both using an Agilent 7693A automatic liquid sampler. Dried
170 samples were suspended in 40 µl of a 40 mg/ml O-methoxylamine hydrochloride (MOX)
171 (MP Bio #155405) in dry pyridine (EMD Millipore #PX2012-7) and incubated for one
172 hour at 37 °C in a sand bath. 25 µl of this solution was added to auto sampler vials. 60
173 µl of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA with 1% TMCS, Thermo
174 #TS48913) was added automatically via the auto sampler and incubated for 30 minutes
175 at 37 °C. After incubation, samples were vortexed and 1 µl of the prepared sample was
176 injected into the gas chromatograph inlet in the split mode with the inlet temperature
177 held at 250°C. A 10:1 split ratio was used for analysis of the majority of metabolites. For
178 those metabolites that saturated the instrument at the 10:1 split concentration, a split of
179 100:1 was used for analysis. The gas chromatograph had an initial temperature of 60°C
180 for one minute followed by a 10°C/min ramp to 325°C and a hold time of 5 minutes
181 followed by a 100°C/min ramp to 375°C. A 30-meter Phenomenex Zebron AB-5HT with
182 5m inert Guardian capillary column was employed for chromatographic separation.
183 Helium was used as the carrier gas at a rate of 1 ml/min.

184 Data was collected using MassHunter software (Agilent). Metabolites were
185 identified and their peak area was recorded using MassHunter Quant. This data was

186 transferred to an Excel spread sheet (Microsoft, Redmond WA). Metabolite identity was
187 established using a combination of an in-house metabolite library developed using pure
188 purchased standards, the NIST library, and the Fiehn library. Values for each metabolite
189 were normalized to the internal standard in each sample and are displayed as fold
190 change compared to the control sample except otherwise indicated in the figure legend.
191 For isotope tracer analysis the area under the curve for each isotope was extracted
192 using MHQuant software (Agilent). This data was exported as a.csv file and isotopically
193 corrected using an in house modified version of DeuteRater (Naylor et al., 2017). All
194 error bars show the mean \pm SE from $N =$ three to four biological replicates analyzed in
195 the same GC-MS run.

196

197 REFERENCES

- 198 Brachmann, C.B., Davies, A., Cost, G.J., Caputo, E., Li, J., Hieter, P., and Boeke, J.D. (1998).
199 Designer deletion strains derived from *Saccharomyces cerevisiae* S288C: a useful set of strains
200 and plasmids for PCR-mediated gene disruption and other applications. *Yeast* *14*, 115-132.
201 10.1002/(SICI)1097-0061(19980130)14:2<115::AID-YEA204>3.0.CO;2-2.
- 202 Canelas, A.B., ten Pierick, A., Ras, C., Seifar, R.M., van Dam, J.C., van Gulik, W.M., and
203 Heijnen, J.J. (2009). Quantitative evaluation of intracellular metabolite extraction techniques for
204 yeast metabolomics. *Anal Chem* *81*, 7379-7389. 10.1021/ac900999t.
- 205 Naylor, B.C., Porter, M.T., Wilson, E., Herring, A., Lofthouse, S., Hannemann, A., Piccolo,
206 S.R., Rockwood, A.L., and Price, J.C. (2017). DeuteRater: a tool for quantifying peptide isotope
207 precision and kinetic proteomics. *Bioinformatics* *33*, 1514-1520. 10.1093/bioinformatics/btx009.
- 208 Sheff, M.A., and Thorn, K.S. (2004). Optimized cassettes for fluorescent protein tagging in
209 *Saccharomyces cerevisiae*. *Yeast* *21*, 661-670. 10.1002/yea.1130.
- 210 Sikorski, R.S., and Hieter, P. (1989). A system of shuttle vectors and yeast host strains designed
211 for efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics* *122*, 19-27.
212